[Editors' Choice] Paths to dyskinesia from nerve cell replacement
DREADDs (designer receptors exclusively activated by designer drugs) reveal a mechanism for dyskinesia induced by transplanted neurons. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - June 14, 2016 Category: Science Authors: Nancy Gough (mailto:ngough at aaas.org) Source Type: news
Extended-Release Amantadine May Improve Levodopa Dyskinesia Control
VANCOUVER — An extended-release amantadine formulation reduced levodopa-induced dyskinesia in a phase III Parkinson’s disease trial from the drug’s developer, Adamas Pharmaceuticals. (Source: Caring for the Ages)
Source: Caring for the Ages - May 28, 2016 Category: Health Management Authors: M. Alexander Otto Source Type: news
Schizophrenia: The Challenges of Taking Medication
For people with schizophrenia, a common question is, “How long is medication needed to treat schizophrenia?” The answer is usually: people most benefit from taking medication for schizophrenia most of their lives. But there are a few challenges with taking any medication for such a long period of time, including reduced effectiveness and unwanted long-term side effects.
Antipsychotic medications — including newer atypical antipsychotics — reduce the risk of future psychotic episodes in patients who have schizophrenia. Even with continued drug treatment, some people will typically suffer relapses ...
Source: Psych Central - May 18, 2016 Category: Psychiatry Authors: Jane Framingham, Ph.D. Tags: Antipsychotics Atypical Antipsychotics Disorders Medications Schizophrenia challenges of taking medication drugs for schizophrenia how long on medication medication for schizophrenia schizophrenia medication side effects of schizophren Source Type: news
New Drug Eases Tardive Dyskinesia in Pivotal Trial
(MedPage Today) -- Tremors related to treatment for schizophrenia quieted by VMAT2 inhibitor (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - April 21, 2016 Category: Psychiatry Source Type: news
Extended-release amantadine may improve levodopa dyskinesia control
VANCOUVER – An extended-release amantadine formulation reduced levodopa-induced dyskinesia in a phase III Parkinson’s disease trial from the drug’s developer, Adamas Pharmaceuticals.
Amantadine... (Source: Clinical Neurology News)
Source: Clinical Neurology News - April 21, 2016 Category: Neurology Source Type: news
Extended-release amantadine may improve levodopa dyskinesia control
VANCOUVER – An extended-release amantadine formulation reduced levodopa-induced dyskinesia in a phase III Parkinson’s disease trial from the drug’s developer, Adamas Pharmaceuticals.
Amantadine... (Source: Family Practice News)
Source: Family Practice News - April 21, 2016 Category: Primary Care Source Type: news
Breakthrough Neuropsychiatric DrugsBreakthrough Neuropsychiatric Drugs
Breakthrough status has recently been granted for novel drugs to treat Parkinson's disease psychosis as well as movement disorders precipitated by antipsychotics, such as tardive dyskinesia. International Journal of Clinical Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 19, 2016 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news
Why I Refuse to Give in to Parkinson's Disease
CBS Photo Archive/CBS via Getty Images The appointment with the neurologist was on March 21, 2007. I was 47 at the time and in pretty good shape. I had never smoked, drank, or took drugs. I worked out four to five times a week. But something was not right. It all began as horrible toe and foot cramps. The little finger on my right (dominant) hand would twitch, and when I played the drums I noticed my right leg was wearing down as if lactic acid was running through my quadriceps. My gait changed; my right arm no longer swinging naturally. Stress brought out the worst of these symptoms; I remember being in a heated phone ...
Source: Healthy Living - The Huffington Post - March 11, 2016 Category: Consumer Health News Source Type: news
FDA grants orphan status for Amarantus' eltoprazine to treat PD-LID
The US Food and Drug Administration (FDA) has granted orphan drug designation for Amarantus BioScience Holdings' (AMBS') eltoprazine to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 11, 2016 Category: Pharmaceuticals Source Type: news
Amarantus Receives Orphan Drug Designation From the US FDA for Eltoprazine in the Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
SAN FRANCISCO, February 10, 2016 -- (Healthcare Sales & Marketing Network) -- Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that... Biopharmaceuticals, Neurology, FDAAmarantus BioScience, Eltoprazine, dyskinesia, Parkinson's disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 10, 2016 Category: Pharmaceuticals Source Type: news
Dipraglurant receives orphan drug designation from the FDA for levodopa-induced dyskinesia associated with Parkinson's disease
Addex Therapeutics, a leading company pioneering allosteric modulation-based drug discovery and development, announced today that the US Food and Drug Administration (FDA) has granted orphan drug... (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - January 4, 2016 Category: Neurology Tags: Parkinson's Disease Source Type: news
Master one of the most missed USMLE questions
With finals behind you, take a few minutes to sharpen your skills for the United States Medical Licensing Examination® (USMLE®) with this exclusive scoop on one of the most challenging USMLE test prep questions and expert strategies to help you ace it. Find out what this month’s toughest question is and receive an expert video explanation of the answer from Kaplan Medical.
Welcome to the fourth post in AMA Wire’s® series, “Tutor talk: Tips from Kaplan Medical on the most missed USMLE test prep questions from Kaplan’s Step 1 Qbank.” Each month, we’re revealing one of the top questions students miss, a helpf...
Source: AMA Wire - December 28, 2015 Category: Journals (General) Authors: Lyndra Vassar Source Type: news
[Editors' Choice] Better treatment for dyskinesia
Enhancing cholinergic signaling reduces a major side effect of ʟ-DOPA therapy in Parkinson's disease models. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - November 25, 2015 Category: Science Authors: Nancy Gough (mailto:ngough at aaas.org) Source Type: news
Teva gets FDA breakthrough status for SD-809 to treat tardive dyskinesia
Israel-based Teva Pharmaceutical Industries has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for SD-809 (deutetrabenazine) to treat patients with moderate to severe tardive dyskinesia, a hyperkinetic moveme… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - November 10, 2015 Category: Pharmaceuticals Source Type: news
Do We Need a New Pill Drill?
Commercials that get into our kids heads drive us crazy. When we see them salivating over enticing ads designed to make them pine for every last morsel of candy, new gimmick or any unhealthy vice, we are outraged. And we should be. It's pretty despicable companies do this. As adults, we are also of great interest to marketers, but the version of "candy" being shoved down our throats -- almost literally -- are prescription meds. The United States, along with New Zealand are the only two countries across the world that allows Direct-to-Consumer (DTC) pharmaceutical advertisements. We turn on our television and are bombar...
Source: Healthy Living - The Huffington Post - October 25, 2015 Category: Consumer Health News Source Type: news
